Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 30.2× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| REGN | VTI | |
|---|---|---|
Market Cap | $76.14B | $2.30T |
Volume | 500,239 | 2,982,924 |
Sector | Health | — |
52-Week High | $852.03 | $384.30 |
52-Week Low | $557.73 | $311.68 |
Typical Hold Time | 107 Days | 131 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
VTI trades at $379.56, down 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad U.S. equity exposure, though key valuation and profitability ratios are not publicly disclosed for the fund itself. Recent news highlights its role in diversified portfolios and long-term growth potential.
The outlook for VTI remains positive given its low-cost, diversified structure and historical performance. Risks include market concentration in top holdings and broader economic volatility. Analyst sentiment is generally favorable for long-term investors seeking total market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
